A Randomized Open-Labeled Trial of Methotrexate as a Steroid-Sparing Agent for Patients With Generalized Myasthenia Gravis
Background and PurposeTwo clinical trials assessing the steroid-sparing effect of methotrexate (MTX) yielded conflicting results. Our objective was to investigate whether MTX would show a steroid-sparing effect in the treatment of generalized myasthenia gravis (MG) patients who fitted Myasthenia Gra...
Sparad:
| Huvudupphov: | , , , , , , |
|---|---|
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Utgiven: |
Frontiers Media S.A.
2022-03-01
|
| Serie: | Frontiers in Immunology |
| Ämnen: | |
| Länkar: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.839075/full |
| Taggar: |
Inga taggar, Lägg till första taggen!
|